Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer

NCT01238133 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

14

Enrollment

NIH

Sponsor class

Conditions

Estrogen Receptor Negative
HER2/Neu Negative
Progesterone Receptor Negative
Stage IIA Breast Cancer
Stage IIB Breast Cancer
Stage IIIA Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Triple-Negative Breast Carcinoma

Interventions

DRUG: Carboplatin
DRUG: Gamma-Secretase Inhibitor RO4929097
OTHER: Laboratory Biomarker Analysis
DRUG: Paclitaxel
OTHER: Pharmacological Study
PROCEDURE: Therapeutic Conventional Surgery

Sponsor

National Cancer Institute (NCI)